If it's not an example of closing the barn door after the horse has run away, then it's 20/20 hindsight. Either way, Daiichi Sankyo has dispatched two execs from Japan--a GM and a director--to keep watch at the new Mohali, Punjab, plant of Indian unit Ranbaxy Labs. The plant is expected to be the main source of Ranbaxy drugs bound for the U.S., and it recently earned an OK from the FDA. Daiichi most likely wants it stay that way: The Japanese drug giant is still smarting from lowering profit projections and cutting exec pay to fund anticipated Ranbaxy fines for allegedly falsifying manufacturing records. Daiichi says the move doesn't indicate a lack of confidence in Ranbaxy's current team. Story